11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
May 2020 in “JAAD case reports” Using anthralin and calcipotriene together might help treat tough cases of alopecia areata, but more research is needed to understand how it works.
October 2023 in “Frontiers in Medicine” Dupilumab helped a 4-year-old grow hair back after another treatment failed.
1 citations
,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
11 citations
,
September 2024 in “American Journal of Clinical Dermatology” Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.
5 citations
,
January 2016 in “European Journal of Dermatology” Suplatast tosilate successfully treated a woman's systemic sclerosis symptoms.
September 2019 in “Journal of Investigative Dermatology” The 3D-SeboSkin model effectively simulates Hidradenitis suppurativa and is useful for future research.
May 2025 in “The Journal of Rheumatology” Anti-CD19 therapy may help treat SLE and NMOSD.
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Samcyprone ointment is effective for treating common warts if a sensitization reaction occurs first.
September 2023 in “Journal of the American Academy of Dermatology”
Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.
49 citations
,
December 2018 in “JAAD case reports” Dupilumab may cause significant hair loss, which can reverse after stopping the drug.
1 citations
,
December 2023 in “Nanomaterials” Combining specific nanoparticles with immune therapy significantly improves cancer treatment.
9 citations
,
January 2023 in “Dermatology and therapy” A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
26 citations
,
July 2019 in “JAAD Case Reports” Dupilumab for atopic dermatitis may cause new or worsen existing alopecia areata.
18 citations
,
February 2025 in “Drug Delivery and Translational Research” The microneedle patches effectively treat allergic conjunctivitis with controlled, sustained release of medication.
October 2013 in “Journal of Investigative Dermatology” Collagen VII helps skin heal and stay strong, sirolimus may lower skin cancer risk in kidney transplant patients, high-molecular-mass hyaluronan helps naked mole rats resist cancer, dermal γδ T cells aid in hair growth in rodents, and overexpression of IL-33 in mouse skin causes itchiness, offering a model for studying allergic inflammation treatments.
18 citations
,
March 1990 in “Archives of Dermatology” Cyclosporine cleared a woman's resistant skin condition quickly and kept it away for over a year.
April 2025 in “JAAD Case Reports” Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.
April 2018 in “Journal of Investigative Dermatology” IL-17C is important in inflammatory skin diseases and could be a target for treatment.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.
7 citations
,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
July 2024 in “Reactions Weekly”
August 2018 in “Journal of The American Academy of Dermatology” Different treatments for skin conditions were found to be effective and generally safe, with biologics recommended as the first choice for generalized pustular psoriasis.
Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.
56 citations
,
September 2016 in “Pharmaceutical Research” The fish oil-based gel with imiquimod improves skin cancer treatment and reduces inflammation.
1 citations
,
June 2019 in “Journal of Cutaneous Immunology and Allergy” Squaric acid dibutylester can cause severe skin reactions in people with allergies.
The new gel effectively treats psoriasis with minimal side effects.
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.